<DOC>
	<DOCNO>NCT02831296</DOCNO>
	<brief_summary>SPOT SMA prospective NIH-supported clinical study target pre-symptomatic recently diagnose infant child Spinal Muscular Atrophy ( SMA ) type 1 , 2 , 3 healthy control sibling less 36 month age time study enrollment . The main objective study prospectively collect longitudinal clinical outcome provide counsel education parent newly diagnose child . The study assess impact current standard care management paradigm intervention health outcome newly diagnose SMA infant child type 1 , 2 3 age appropriate control . There investigational drug specific intervention study . Rather , investigator document outcomes related current therapy provide participate subject , educate participant possible clinical trial opportunity .</brief_summary>
	<brief_title>Prospective Evaluation Infants With Spinal Muscular Atrophy :</brief_title>
	<detailed_description>Overview data collect enrolled infant follow longitudinally enter NBSTRN Longitudinal Pediatric Data Resource 1 . Past medical history relevant pregnancy , delivery , complication immediate neonatal period , birth parameter , family history medical problem SMA ( ie prematurity , etc ) 2 . Ongoing medical history indicate problem relate follow area : feeding , growth , respiratory status include use cough assist bilevel respiratory support , gastrointestinal issue , cardiac symptom , neurologic symptom sign include muscle weakness , hospitalization , ER visit , adverse event 3 . Assessment dietary intake use nutritional supplement 4 . Surgical history ongoing documentation assessment need g-tube , Nissen , tympanostomy , adenoidectomy/tonsillectomy airway surgery , orthopedic procedure 5 . Caregiver obtain developmental history documentation newly acquire and/or loss previously acquire gross motor skill time visit 6 . Documentation caregiver report outcomes 7 . Documentation anthropometric measure , vital sign , general physical examination parameter 8 . Neurological examination use standardized tool 9 . Time death , permanent invasive ventilation and/or need &gt; 16 hours/day bilevel respiratory support 10 . Specific assessment motor function measure use age appropriate motor outcome measure : Children 's Hospital Philadelphia Infant Tests Neuromuscular Disorders ( CHOP-INTEND ) , Test Infant Motor Performance Screening Inventory , WHO motor milestone others , Hammersmith Functional Motor Scale SMA Expanded child 18 month old 11 . Electrophysiologic study maximum ulnar compound muscle action potential ( CMAP ) amplitude area 12 . Documentation range motion , development limb contracture and/or presence scoliosis , lordosis , hip dysplasia orthopedic outcomes 13 . Additional optional exploratory biomarker assessments 14 . DEXA measurement ass body composition bone density 15 . The option enroll autopsy study time death contribute sample research biorepository Normal control subject unaffected sibling undergo measurement , applicable . Unaffected parent ' participation limit collection banking blood cell line .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>For affect unaffected ( control ) infants child : 36 month age young time enrollment For affected subject : genetic diagnosis SMA For unaffected family member : parent sibling age ( without genetic diagnosis SMA ) affect subject enrol study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>SMA</keyword>
	<keyword>Werdnig-Hoffmann disease</keyword>
	<keyword>Kugelberg-Welander disease</keyword>
</DOC>